
Please try another search
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China and internationally. The company’s product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; and SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia. It is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment. In addition, the company sells biopharmaceutical drugs. The company was founded in 2007 and is headquartered in Shanghai, the People’s Republic of China.
Name | Age | Since | Title |
---|---|---|---|
Xiaodong Wang | 62 | 2021 | Non-Executive Director |
Xiang Liao | 59 | 2021 | Independent Non-Executive Director |
Jeffrey S. Farrow | 63 | 2021 | Independent Non-Executive Director |
Donna Marie Ambrosino | 73 | 2022 | Non-Executive Director |
Thomas Edward Leggett | 48 | 2021 | Independent Non-Executive Director |
Joshua G. Liang | 32 | 2020 | CEO & Executive Director |
Xiaobin Wu | 63 | 2021 | Independent Non-Executive Director |
Peng Liang | 64 | 2018 | Founder, Chief Scientific Officer & Chairman of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review